Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(tested or 100% immunogen sequence identity)
Western blot (1:1000)
ELISA (1:1000 - 1:4000)
NF2 / Merlin antibody was raised against human Merlin (NF2) phosphorylated peptide corresponding to a region of the human protein surrounding Ser518; labeled with KLH.
Recognizes human Merlin (NF2) phosphorylated at Ser518, Mr 75kD. Specific for the phosphorylated form of human Merlin (NF2). Less than 5% cross-reactivity was detected against the non-phosphorylated form of the immunizing peptide. Species cross-reactivity: Mouse.
Suitable for use in ELISA and Western Blot. ELISA: 1:1000-1:4000. Use 0.1 ug phosphorylated peptide in a standard capture ELISA using TMB as a substrate for 30 minutes at RT. Western Blot: 1:1000. Positive control: WB: Mouse cardiac myocyte lysate.
PBS, pH 7.2, 0.01% Sodium Azide, No stabilizing proteins added
Short term: 4°C; Long term: Add glycerol (40-50%) -20°C.
Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity.